$NTRA

Rabinowitz Matthew sold $21.4M of NTRA

Rabinowitz Matthew (EXECUTIVE CHAIRMAN) sold 100,000 shares of Natera, Inc. (NTRA) at an average of $214.47 ($209.50–$219.36, $21.45M total) across 21 trades over 2026-06-12 to 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rabinowitz Matthew
Published Jun 17, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 2:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure provides a concrete, time-stamped insider selling event (open-market sale) with a disclosed weighted-average price range and post-transaction holdings, which can influence short-term sentiment and positioning.

02

Market read

A large insider sale (~$21.45M) was reported, but the presence of a 10b5-1 plan suggests reduced informational content versus unscheduled selling.

03

What to watch

Traders may over-weight the headline size; the key is whether there are additional insider sales around the same window or any concurrent fundamental disclosures not included here.

Relevance 6/10Novelty 8/10Timing: Filed 2026-06-16; trades occurred 2026-06-12 to 2026-06-15.

Background

The article summarizes an SEC Form 4 insider transaction for Natera, Inc. (NTRA) by executive chairman Matthew Rabinowitz.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera executive chairman Matthew Rabinowitz sold about 100,000 shares in open-market trades for ~$21.45M under a 10b5-1 plan.

Expected impact

Likely limited, short-lived negative bias unless follow-on selling or other fundamentals emerge.

Evidence & confidence

The filing is a primary-source Form 4 showing a large sale, yet it is explicitly pre-arranged under Rule 10b5-1, which typically dampens interpretation of insider conviction.

Market effects

No direct sector read-through; this is company-specific insider liquidity/positioning rather than a sector catalyst.

Minimal; US-listed single-name insider transaction.

Low; no cross-border deal/regulatory element described.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled diversification/liquidity needs rather than bearish expectations.

Key entities

  • Natera, Inc.

    US-listed company whose executive chairman sold shares via open-market transactions under a 10b5-1 plan.

  • Matthew Rabinowitz

    Executive Chairman and director who executed the reported sales.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAHigh

Why Natera (NTRA) Stock Is Up Today

Natera (NTRA) stock rose 2.2% after the FDA granted Breakthrough Device designation to its multi-cancer early detection assay. The assay showed promising performance data across 12 cancer types. The company's shares are up 74.9% year-to-date, trading near a 52-week high of $425.64. Natera plans a commercial launch in Japan in 2027 for its Signatera test, approved as a companion diagnostic for bladder cancer.

$NTRAHigh

Natera Receives FDA Breakthrough Device Designation for Multi-Cancer Early Detection Blood Test

Natera (NTRA) received FDA Breakthrough Device Designation for its multi-cancer early detection blood test, based on clinical data covering 12 cancer types. The designation accelerates regulatory review but does not guarantee approval. The test analyzes cell-free DNA to detect cancer signals and their likely origin. Natera aims to expand early cancer detection options, though clinical performance and benefits require further evaluation.